UY40256A - Formas de sales y cristales de un inhibidor del receptor del factor de crecimiento epidérmico - Google Patents
Formas de sales y cristales de un inhibidor del receptor del factor de crecimiento epidérmicoInfo
- Publication number
- UY40256A UY40256A UY0001040256A UY40256A UY40256A UY 40256 A UY40256 A UY 40256A UY 0001040256 A UY0001040256 A UY 0001040256A UY 40256 A UY40256 A UY 40256A UY 40256 A UY40256 A UY 40256A
- Authority
- UY
- Uruguay
- Prior art keywords
- growth factor
- factor receptor
- epidermal growth
- salt
- crystal forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263338371P | 2022-05-04 | 2022-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY40256A true UY40256A (es) | 2023-11-15 |
Family
ID=86688767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001040256A UY40256A (es) | 2022-05-04 | 2023-05-04 | Formas de sales y cristales de un inhibidor del receptor del factor de crecimiento epidérmico |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250282761A1 (enExample) |
| EP (1) | EP4519254A1 (enExample) |
| JP (1) | JP2025517634A (enExample) |
| KR (1) | KR20250012078A (enExample) |
| CN (1) | CN119923392A (enExample) |
| AU (1) | AU2023265064A1 (enExample) |
| CA (1) | CA3251624A1 (enExample) |
| IL (1) | IL316663A (enExample) |
| MX (1) | MX2024013485A (enExample) |
| TW (1) | TW202409016A (enExample) |
| UY (1) | UY40256A (enExample) |
| WO (1) | WO2023215431A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024097270A1 (en) * | 2022-11-01 | 2024-05-10 | Blueprint Medicines Corporation | Egfr inhibitors for treatment of cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113493419A (zh) * | 2020-03-18 | 2021-10-12 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| CN113493420B (zh) * | 2020-03-18 | 2025-04-25 | 南京迈晟科技有限责任公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| IL302457A (en) * | 2020-10-30 | 2023-06-01 | Blueprint Medicines Corp | Pyrimidine compounds, preparations and their medical applications |
| CA3196857A1 (en) * | 2020-10-30 | 2022-05-05 | Gurulingappa Hallur | Pyrimidine compounds, compositions, and medicinal applications thereof |
-
2023
- 2023-05-04 EP EP23728478.1A patent/EP4519254A1/en active Pending
- 2023-05-04 US US18/862,859 patent/US20250282761A1/en active Pending
- 2023-05-04 CN CN202380051632.8A patent/CN119923392A/zh active Pending
- 2023-05-04 IL IL316663A patent/IL316663A/en unknown
- 2023-05-04 TW TW112116649A patent/TW202409016A/zh unknown
- 2023-05-04 UY UY0001040256A patent/UY40256A/es not_active Application Discontinuation
- 2023-05-04 AU AU2023265064A patent/AU2023265064A1/en active Pending
- 2023-05-04 WO PCT/US2023/020925 patent/WO2023215431A1/en not_active Ceased
- 2023-05-04 KR KR1020247040290A patent/KR20250012078A/ko active Pending
- 2023-05-04 CA CA3251624A patent/CA3251624A1/en active Pending
- 2023-05-04 JP JP2024564833A patent/JP2025517634A/ja active Pending
-
2024
- 2024-10-31 MX MX2024013485A patent/MX2024013485A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202409016A (zh) | 2024-03-01 |
| AU2023265064A1 (en) | 2024-11-14 |
| US20250282761A1 (en) | 2025-09-11 |
| MX2024013485A (es) | 2024-12-06 |
| IL316663A (en) | 2024-12-01 |
| WO2023215431A1 (en) | 2023-11-09 |
| EP4519254A1 (en) | 2025-03-12 |
| JP2025517634A (ja) | 2025-06-10 |
| CN119923392A (zh) | 2025-05-02 |
| KR20250012078A (ko) | 2025-01-23 |
| CA3251624A1 (en) | 2023-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017009891A2 (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta) | |
| CO2022008091A2 (es) | Inhibidores de kras g12c | |
| CO2024012743A2 (es) | Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias | |
| PY1996328A (es) | Compuestos de azalactam como inhibidores de hpk1 | |
| PE20250667A1 (es) | Formas solidas, sales y procesos de preparacion de un inhibidor de cdk2 | |
| UY38553A (es) | Inhibidores de cdk2 | |
| CO2023001579A2 (es) | Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de este | |
| UY39517A (es) | Inhibidores de la btk | |
| UY38144A (es) | Inhibidores de la señalización mediada por tirosina cinasa | |
| MX2020007947A (es) | Inhibidores de erbb/btk. | |
| AR047917A1 (es) | Derivados de 4-benzimidazol-2-il-piridazin-3-ona, preparacion de los mismos, y su empleo en medicamentos | |
| CO2022018806A2 (es) | Inhibidores de las cinasas receptoras del receptor del factor de crecimiento de fibroblastos | |
| MX2022000550A (es) | Imidazopirimidinas como inhibidores de eed y uso de estas. | |
| CO2024012423A2 (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
| CL2023000712A1 (es) | Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenos | |
| UY38233A (es) | Agentes inhibidores para la tirosina cinasa de bruton | |
| MX2024009161A (es) | Compuestos de pirrolidina. | |
| CL2024003274A1 (es) | Métodos para producir compuestos halogenados | |
| CL2025002615A1 (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| CL2025000672A1 (es) | Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer. | |
| CO2024011857A2 (es) | Compuestos de uracilo n3-sustituidos como inhibidores de trpa1 | |
| MX2021004917A (es) | Sales cristalinas de un inhibidor de calicreina plasmatica. | |
| ECSP23091202A (es) | Moduladores de trex1 | |
| MX2024013485A (es) | Formas salinas y cristalinas de un inhibidor del receptor del factor de crecimiento epidermico | |
| DOP2025000285A (es) | Inhibidores de ciclina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 104 | Application deemed to be withdrawn (no substantive examination fee paid) |
Effective date: 20240513 |